Phase II Study Evaluating the Efficacy and Safety of Ociperlimab in Combination With Tislelizumab and Chemotherapy as First-line Treatment for Participants With Advanced Triple Negative Breast Cancer
Clinical trial NCT05809895 · WITHDRAWN
Trial details
- NCT number
- NCT05809895
- Sponsor
- Novartis Pharmaceuticals
- Status
- WITHDRAWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-09-15
- Primary completion
- 2029-07-17
- Enrollment
- 0
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.